• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

毛细血管前肺动脉高压和右心室扩张可预测心脏再同步治疗的临床结局。

Pre-capillary pulmonary hypertension and right ventricular dilation predict clinical outcome in cardiac resynchronization therapy.

机构信息

Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Cardiac Arrhythmia Service, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

出版信息

JACC Heart Fail. 2014 Jun;2(3):230-7. doi: 10.1016/j.jchf.2014.02.004. Epub 2014 Apr 30.

DOI:10.1016/j.jchf.2014.02.004
PMID:24952689
Abstract

OBJECTIVES

This study examined the prognostic significance of pre- and post-capillary components of pulmonary hypertension (PH) in patients receiving cardiac resynchronization therapy (CRT).

BACKGROUND

PH is common in patients with left ventricular systolic dysfunction (LVSD) receiving CRT. The impact of PH subtype on clinical outcome in CRT is unknown.

METHODS

The study population consisted of 101 patients (average age 66 ± 13 years, left ventricular ejection fraction 0.23 ± 0.07, and New York Heart Association functional class 3.2 ± 0.4) who underwent right heart catheterization in the 6 months before CRT. PH was defined as a mean pulmonary artery pressure ≥25 mm Hg; a significant pre-capillary contribution to elevated mean pulmonary artery pressure was defined as a transpulmonary gradient (TPG) ≥12 mm Hg. Clinical endpoints were assessed at 2 years and included all-cause mortality and a composite of death, left ventricular assist device, or cardiac transplantation.

RESULTS

Patients with TPG ≥12 mm Hg were more likely to experience all-cause mortality (hazard ratio [HR]: 3.2; 95% confidence interval [CI]: 1.3 to 7.4; p = 0.009) and the composite outcome (HR: 3.0; 95% CI: 1.4 to 6.3; p = 0.004) compared with patients with TPG <12 mm Hg. After multivariate adjustment for hemodynamic, clinical, and echocardiographic variables, only TPG ≥12 mm Hg and baseline right ventricular (RV) dilation (RV end-diastolic dimension >42 mm) were associated with the composite clinical outcome (p = 0.05 and p = 0.04, respectively).

CONCLUSIONS

High TPG PH and RV dilation are independent predictors of adverse outcomes in patients with LVSD who are receiving CRT. RV pulmonary vascular dysfunction may be a therapeutic target in select patients receiving CRT.

摘要

目的

本研究探讨了接受心脏再同步治疗(CRT)的患者肺高血压(PH)的毛细血管前和毛细血管后成分的预后意义。

背景

PH 在接受 CRT 的左心室收缩功能障碍(LVSD)患者中很常见。PH 亚型对 CRT 临床结局的影响尚不清楚。

方法

研究人群包括 101 例患者(平均年龄 66±13 岁,左心室射血分数 0.23±0.07,纽约心脏协会功能分级 3.2±0.4),他们在 CRT 前 6 个月接受了右心导管检查。PH 定义为平均肺动脉压≥25mmHg;肺动脉压升高有显著的毛细血管前贡献,定义为跨肺梯度(TPG)≥12mmHg。临床终点在 2 年内评估,包括全因死亡率和死亡、左心室辅助装置或心脏移植的复合终点。

结果

TPG≥12mmHg 的患者更有可能经历全因死亡率(风险比[HR]:3.2;95%置信区间[CI]:1.3 至 7.4;p=0.009)和复合终点(HR:3.0;95%CI:1.4 至 6.3;p=0.004),与 TPG<12mmHg 的患者相比。多变量调整血流动力学、临床和超声心动图变量后,仅 TPG≥12mmHg 和基线右心室(RV)扩张(RV 舒张末期内径>42mm)与复合临床结局相关(p=0.05 和 p=0.04)。

结论

高 TPG PH 和 RV 扩张是接受 CRT 的 LVSD 患者不良结局的独立预测因子。在接受 CRT 的特定患者中,RV 肺血管功能障碍可能是一个治疗靶点。

相似文献

1
Pre-capillary pulmonary hypertension and right ventricular dilation predict clinical outcome in cardiac resynchronization therapy.毛细血管前肺动脉高压和右心室扩张可预测心脏再同步治疗的临床结局。
JACC Heart Fail. 2014 Jun;2(3):230-7. doi: 10.1016/j.jchf.2014.02.004. Epub 2014 Apr 30.
2
Diastolic Pulmonary Gradient as a Predictor of Right Ventricular Failure After Left Ventricular Assist Device Implantation.舒张期肺动脉梯度作为左心室辅助装置植入后右心衰竭的预测因子。
J Am Heart Assoc. 2019 Aug 20;8(16):e012073. doi: 10.1161/JAHA.119.012073. Epub 2019 Aug 14.
3
Relation of right ventricular peak systolic pressure to major adverse events in patients undergoing cardiac resynchronization therapy.心脏再同步治疗患者右心室收缩压峰值与主要不良事件的关系。
Am J Cardiol. 2006 Jun 15;97(12):1737-40. doi: 10.1016/j.amjcard.2006.01.033. Epub 2006 Apr 24.
4
Usefulness of hyponatremia as a predictor for adverse events in patients with heart failure receiving cardiac resynchronization therapy.低钠血症对心力衰竭接受心脏再同步化治疗患者不良事件的预测价值。
Am J Cardiol. 2014 Jul 1;114(1):83-7. doi: 10.1016/j.amjcard.2014.04.009. Epub 2014 Apr 18.
5
Effect of Cardiac Resynchronization Therapy on Exercise-Induced Pulmonary Hypertension and Right Ventricular-Arterial Coupling.心脏再同步治疗对运动诱导性肺动脉高压和右心室-动脉偶联的影响。
Circ Cardiovasc Imaging. 2018 Sep;11(9):e007813. doi: 10.1161/CIRCIMAGING.118.007813.
6
A clinical phenotype of adverse response to biventricular pacing: a case series.双心室起搏不良反应的临床表型:病例系列
Pacing Clin Electrophysiol. 2013 Apr;36(4):410-5. doi: 10.1111/pace.12067. Epub 2013 Jan 10.
7
Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial.心脏再同步治疗对无症状或轻度症状性左心室功能不全患者疾病进展的预防作用:来自欧洲队列的REVERSE(收缩期左心室功能不全再同步逆转重塑)试验的见解
J Am Coll Cardiol. 2009 Nov 10;54(20):1837-46. doi: 10.1016/j.jacc.2009.08.011. Epub 2009 Oct 1.
8
Prediction of right ventricular dysfunction after left ventricular assist device implantation.左心室辅助装置植入术后右心室功能障碍的预测
Circulation. 1996 Nov 1;94(9 Suppl):II216-21.
9
Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE).植入式心脏除颤器可改善接受心脏再同步治疗的轻度症状性心力衰竭患者的生存率:收缩性左心室功能障碍(REVERSE)重构长期随访分析。
Circ Arrhythm Electrophysiol. 2013 Dec;6(6):1163-8. doi: 10.1161/CIRCEP.113.000570. Epub 2013 Oct 14.
10
Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study.QRS 时限和形态对轻度心力衰竭心脏再同步治疗结局的影响:来自同步化逆转左心室收缩功能障碍重构(REVERSE)研究的结果。
Circulation. 2012 Aug 14;126(7):822-9. doi: 10.1161/CIRCULATIONAHA.112.097709. Epub 2012 Jul 10.

引用本文的文献

1
Can Right Heart Catheterization Improve the Prediction of Positive Response to Resynchronization Therapy?右心导管检查能否改善对心脏再同步治疗阳性反应的预测?
Biomedicines. 2025 Feb 14;13(2):467. doi: 10.3390/biomedicines13020467.
2
Right ventricular-pulmonary artery coupling in patients undergoing cardiac resynchronization therapy.右心室-肺动脉耦联在心脏再同步治疗患者中的应用。
Int J Cardiovasc Imaging. 2024 Nov;40(11):2325-2334. doi: 10.1007/s10554-024-03233-5. Epub 2024 Sep 5.
3
Right ventricular-pulmonary artery coupling in cardiac resynchronization therapy: evolution and prognosis.
右心室-肺动脉耦联在心脏再同步治疗中的作用:演变和预后。
ESC Heart Fail. 2022 Jun;9(3):1597-1607. doi: 10.1002/ehf2.13857. Epub 2022 Mar 9.
4
Detrimental effects of elevated transpulmonary gradient on outcomes following restrictive mitral annuloplasty in patients with pre-existing pulmonary hypertension.对于已有肺动脉高压的患者,经肺梯度升高对限制性二尖瓣环成形术后预后的有害影响。
J Thorac Dis. 2021 May;13(5):2746-2757. doi: 10.21037/jtd-20-2898.
5
Ratio between Right Ventricular Longitudinal Strain and Pulmonary Arterial Systolic Pressure: Novel Prognostic Parameter in Patients Undergoing Cardiac Resynchronization Therapy.右心室纵向应变与肺动脉收缩压之比:心脏再同步治疗患者的新预后参数。
J Clin Med. 2021 May 31;10(11):2442. doi: 10.3390/jcm10112442.
6
A prognostic nomogram for event-free survival in patients with atrial fibrillation before cardiac resynchronization therapy.心房颤动患者心脏再同步治疗前无事件生存的预后列线图。
BMC Cardiovasc Disord. 2020 May 13;20(1):221. doi: 10.1186/s12872-020-01502-4.
7
Echocardiographic Assessment of Right Ventriculo-arterial Coupling: Clinical Correlates and Prognostic Impact in Heart Failure Patients Undergoing Cardiac Resynchronization Therapy.右心室-动脉耦联的超声心动图评估:接受心脏再同步治疗的心力衰竭患者的临床关联及预后影响
J Cardiovasc Imaging. 2020 Apr;28(2):109-120. doi: 10.4250/jcvi.2019.0094. Epub 2020 Jan 21.
8
Relationship of soluble ST2 to pulmonary hypertension severity in patients undergoing cardiac resynchronization therapy.心脏再同步治疗患者中可溶性ST2与肺动脉高压严重程度的关系。
J Thorac Dis. 2019 Dec;11(12):5362-5371. doi: 10.21037/jtd.2019.11.66.
9
Prognostication of Poor Survival After Cardiac Resynchronization Therapy.心脏再同步化治疗后预后不良的预测。
Medicina (Kaunas). 2020 Jan 4;56(1):19. doi: 10.3390/medicina56010019.
10
Cardiac Resynchronization Therapy-Emerging Therapeutic Approaches.心脏再同步治疗——新兴治疗方法
Curr Treat Options Cardiovasc Med. 2018 Mar 6;20(3):20. doi: 10.1007/s11936-018-0614-2.